Lambrinex (Atorvastatin)

Atorvastatin inhibits the enzyme HMG‑CoA reductase in the liver, the key step in cholesterol synthesis. This leads to reduced hepatic cholesterol production, up‑regulation of LDL receptors, and increased removal of LDL cholesterol from the bloodstream, improving the overall lipid profile.

The appropriate dose of Lambrinex is determined by a qualified prescriber based on the individual’s lipid levels, cardiovascular risk, age, renal function and concomitant medications. Patients should follow the dosing instructions provided by their healthcare professional.

Statins, including atorvastatin, are generally contraindicated during pregnancy because of potential fetal harm. Use during breastfeeding is also not recommended unless the benefits outweigh the risks. Patients who are pregnant, planning pregnancy, or nursing should discuss alternatives with their clinician.

To place an order, submit an enquiry on the Lambrinex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Atorvastatin is a high‑potency statin with a long half‑life, offering strong LDL‑cholesterol reduction at relatively low doses compared with some older statins. Its efficacy, safety profile and once‑daily dosing make it a common choice for patients needing substantial lipid lowering.

Lambrinex should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or temperature fluctuations.

Lambrinex is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include rhabdomyolysis, a severe form of muscle breakdown that can lead to kidney failure, and significant liver injury. Patients should promptly report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice.

Lambrinex should be avoided in individuals with active liver disease, unexplained persistent elevations of serum transaminases, known hypersensitivity to atorvastatin or any excipients, and in pregnant or nursing women unless a clinician determines the benefits outweigh the risks.